

Bulletin from the Meda AB (publ) extraordinary general meeting (EGM)

Today, Meda's EGM unanimously approved the board's decision to increase the company's share capital by no more than SEK 23,220,968 to at most SEK 232,209,684. Consequently, at most 11,610,484 series A shares will be subscribed for within the new share issue. The new shares will be issued at a subscription price of SEK 160 per share. Shareholders have preferential rights to subscribe for one (1) new share for nine (9) old shares.

Important dates for the new share issue
Shares are listed ex-right to participation
Record date for the right to participate
Subscription period

11 January 2007 15 January 2007

19 January - 8 February 2007

A prospectus regarding the invitation to subscribe for shares in Meda AB (publ) in the 2007 share issue is held available on the company's homepage, www.meda.se, and can also be received at:

- Meda AB, Pipers väg 2A, SE-170 09 Solna, Sweden, and
- SEB Enskilda, Skandinaviska Enskilda Banken AB, Kungsträdgårdsgatan 8, SE-106 40 Stockholm, Sweden

Solna, Sweden, 10 January 2007

The Board

MEDA AB (publ) is a leading European specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda has own affiliates in 24 countries and more than 1000 employees within marketing and sales. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit www.meda.se